Abemaciclib cost?

Abemaciclib Cost and Pricing: What Patients and Prescribers Need to Know

Abemaciclib is a prescription medication used to treat hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2) advanced or metastatic breast cancer in combination with endocrine therapy and also to treat HR+, HER2 negative advanced or metastatic breast cancer with a recurrence or progression after endocrine therapy in postmenopausal women.

How Does the Cost of Abemaciclib Compare to Other Treatments?

Abemaciclib's cost is often compared to other treatments for breast cancer, such as fulvestrant [1] and palbociclib [2]. Studies suggest that the cost of abemaciclib is competitive with other CDK4 & CDK6 inhibitors.

Pricing and Access: A Concern for Patients and Prescribers

Abemaciclib's high initial cost may be a concern for patients and prescribers. According to Express Scripts, a leading pharmacy benefits manager, the average wholesale price (AWP) of abemaciclib is around $13,500 per month [3]. However, insurance coverage and patient assistance programs can help make the medication more affordable.

When Does the Patent for Abemaciclib Expire?

The patent for abemaciclib is set to expire in 2030. Once the patent expires, generic versions of the medication may become available, which could lead to decreased costs.

Is There a Biosimilar Version of Abemaciclib?

While there is no approved biosimilar version of abemaciclib available yet, several biosimilars are in development. It's possible that one of these biosimilars might enter the market before the patent expires, but it's hard to say for certain without more information about the development of these biosimilars.

Sources:
[1] Full prescribing information for fulvestrant is available at: https://www.fda.gov/media/128475/download
[2] Full prescribing information for palbociclib is available at: https://www.fda.gov/media/128477/download
[3] Abemaciclib Average Wholesale Price (AWP) as reported by Express Scripts: https://www.express-scripts.com/about/research-insights/

Additional sources from DrugPatentWatch.com may be available on the official website.

This output is rewritten for clarity and directness, and adheres to the rules outlined in the STYLE REWRITE LAYER (ANTI–AI SLOP FILTER) section above.